The recent development of selective antagonists of the cannabinoid receptors, CB1 and CB2, has permitted a much greater level of certainty in the interpretation of pharmacological data.

Past research has shown that activating CB1 and CB2 receptors with plant-derived compounds can slow down early tumor growth in various cancers, as they act as mediators, triggering different ...

The CB1 and CB2 cannabinoid receptors mentioned earlier also interact with phytocannabinoids. Some compounds, like THC and ...

The study is published in the journal iScience. Cannabis binds to the so-called Cannabinoid receptor 1 (CB1 receptor), one of the most common receptors in our brain. CB1 receptors serve as ...

SOLANA BEACH, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop ...